Mark Perkins, PhD, reviews some of the important factors involved, and highlights the advantages of including recombinant human albumin to stabilize protein therapeutics with reference to a recent case study.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part I of III
In the past two columns, The Second Quadrant focused on excipients and the roles they play in the quest to overcome bioavailability challenges of poorly…
In June’s edition of The Second Quadrant, we heard from leading excipient providers about challenges faced directly related to formulating with excipients for greater bioavailability.…
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
Philip J. Butler and Thorsten Cech investigate the gastric-resistant functionality obtained by applying a clear, two-component MAE coating formulation onto a tablet sub-coated with a pigmented instant-release coating and investigate the impact of hydrophilic and lipophilic plasticizers on the film characteristics of MAE-based coating formulations.
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., begins his multiple-part series discussing today’s most challenging issues in solubility.
Hans Ole Klingenberg explains how Bacillus-derived HA offers new opportunities for ophthalmic applications by providing a safe and biocompatible source that can streamline manufacturing processes, while offering convenient application and increased patient comfort and compliance.
EXECUTIVE INTERVIEW – Agere: Solubilization: Accessing Broader Chemistries by Integrating Fundamental Science With Automation for Greater Predictability
Drug Development Executive: Marshall Crew, President & CEO of Agere, discusses how the company is taking a different approach that leverages expertise, but relies heavily on the principles of physical chemistry to enable automation.
EXCIPIENT UPDATE – Addressing Challenges With Low-Solubility Compounds: The Importance of Functional Excipients in the Formulation of Amorphous Dispersions
Rod Ray, PhD, explains that because more than half of the compounds in early development are considered poorly soluble, improving oral bioavailability represents a significant challenge to the pharmaceutical industry.
Robert Gwozdz, MPharm, presents an overview of polymers used in the more exotic and technically challenging dosage forms involving MR as well as those used for enhancing the dissolution and bioavailability of poorly soluble APIs.
EXCLUSIVE ONLINE CONTENT
Evonik Launches New Oral Drug Delivery Technology for Enteric Protection & Rapid Release in the Upper Small Intestine
Evonik has recently launched an advanced oral drug delivery technology that provides enteric protection followed by rapid, homogeneous release for effective….
Evonik recently announced the qualification of an advanced aseptic filling line for complex parenteral drug products at its FDA-inspected Birmingham….
Croda International Plc recently announced it has agreed to acquire Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for next-generation pharmaceuticals…..
ABITEC Corporation, an ABF Ingredients company, announced today that it has acquired Larodan AB, a manufacturer and international marketer of state of the art, high-purity research grade lipids…..
Wondering if investing in a higher purity excipient is really going to pay off? Check out our video web series where we speak to 3 subject matter experts on the benefits of…..